異位性皮膚炎治療藥物的全球市場規模、佔有率和成長分析：按給藥途徑和藥物類別 - 產業預測（2024-2031）

Global Atopic Dermatitis Drugs Market Size, Share, Growth Analysis, By Route of administration(Topical, injection and others), By Drug class(Biologics, PDE4 inhibitors) - Industry Forecast 2024-2031

出版日期: 2024年03月18日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

異位性皮膚炎治療藥物的全球市場規模在2022年估值為136.5億美元，在預測期內(2024~2031年)從2023年的149.1億美元成長到2031年的301.4億美元，複合年成長率為9.2%。

在製藥業，治療異位性皮膚炎（也稱為濕疹）的藥物的開發、製造和分銷是動態且快速成長的全球皮膚炎藥物市場的焦點。由於全球異位性皮膚炎盛行率不斷上升以及對安全有效治療方法的需求不斷增加，該行業正在經歷顯著擴張。知名製藥公司正在進行激烈的競爭，並努力推出創新藥物和治療方法，以滿足異位性皮膚炎患者未滿足的需求。技術的發展，包括靶向給藥系統、用於症狀監測和管理的穿戴式設備，以及能夠對異位性皮膚炎患者進行遠端諮詢和個人化治療的遠端醫療平台，也為該行業提供了支持。外用皮質類固醇、Calcineurin抑制劑、免疫調節劑和生物製藥只是市面上可用的眾多治療方法中的一小部分，每種藥物都有特殊的作用機制和益處。科技的發展也在幫助該行業，包括靶向給藥系統、追蹤和管理症狀的穿戴式設備，以及為異位性皮膚炎患者提供遠端諮詢和個人化治療的遠端醫療平台。精準醫療和個人化醫療圍繞著重點藥物越來越受歡迎，以提高患者滿意度和治療成功率。該行業的創新也受到戰略合作夥伴關係、研發計劃和技術改進的推動。這些因素為異位性皮膚炎患者提供了更客製化、更有效的解決方案，預示著更光明的未來。

Pfizer Inc.（US）
Sanofi（France）
AbbVie Inc.（US）
GALDERMA LABORATORIES, LP（Switzerland）
Eli Lilly and Company（US）
Regeneron Pharmaceuticals Inc.（US）
LEO Pharma Inc.（Denmark）
Otsuka Pharmaceutical Co., Ltd.（Japan）
Novartis AG（Switzerland）
Incyte Corporation（US）
Astellas Pharma Inc.（Japan）
Bristol Myers Squibb（US）
Johnson & Johnson（US）
Takeda Pharmaceutical Company Limited（Japan）
GlaxoSmithKline plc（UK）
Boehringer Ingelheim International GmbH（Germany）
Celgene Corporation（US）
Meda AB（Sweden）
Pierre Fabre Group（France）
Bayer AG（Germany）

簡介目錄

Product Code: SQMIG35I2166

Global Atopic Dermatitis Drugs Market size was valued at USD 13.65 billion in 2022 and is poised to grow from USD 14.91 billion in 2023 to USD 30.14 billion by 2031, growing at a CAGR of 9.2% during the forecast period (2024-2031).

In the pharmaceutical industry, the development, manufacturing, and distribution of drugs for the treatment of atopic dermatitis, also referred to as eczema, is the focus of the dynamic and quickly growing global dermatitis drugs market. Due to the rising global prevalence of atopic dermatitis and the rising need for safe and efficient treatment alternatives, the industry has experienced substantial expansion. Prominent pharmaceutical corporations are involved in intense rivalry, endeavoring to present innovative medications and treatments to address the unfulfilled requirements of atopic dermatitis patients. Technological developments include targeted drug delivery systems, wearables for symptom monitoring and management, and telemedicine platforms that allow for remote consultations and individualized treatment for people with atopic dermatitis are also helping the industry. Topical corticosteroids, calcineurin inhibitors, immunomodulators, and biologic medicines are only a few of the many therapeutic methods available on the market; each has a special mode of action and advantages. Technological developments include targeted drug delivery systems, wearables for tracking and controlling symptoms, and telemedicine platforms that allow for remote consultations and individualized treatment for people with atopic dermatitis are also helping the industry. Precision medicine and personalized care are gaining popularity, with a focus on focused medicines to improve patient satisfaction and treatment success. Innovation in this industry is also being driven by strategic partnerships, R&D initiatives, and technology improvements. These factors promise a bright future with more customized and effective solutions for people with atopic dermatitis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atopic Dermatitis Drugs Market Segmental Analysis

The medicine class, region, and mode of administration are the three main segments of the global market for atopic dermatitis drugs. The market can be divided into injectable, topical, and other categories based on the mode of administration. The market is divided into segments based on drug class, including biologics, PDE4 inhibitors, corticosteroids, and others. The market is divided into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America based on geographic factors.

Drivers of the Global Atopic Dermatitis Drugs Market

The rising incidence of atopic dermatitis throughout the globe is one of the main factors propelling the global market for atopic dermatitis drugs. Atopic dermatitis is a widespread, long-lasting inflammatory skin disease that affects a large number of people worldwide, both adults and children. Numerous variables, including lifestyle modifications, environmental triggers, and genetic predisposition, might be blamed for the increasing prevalence of atopic dermatitis. The increasing number of people affected by atopic dermatitis is increasing the need for efficient treatment alternatives that will reduce symptoms and enhance their quality of life. Pharmaceutical businesses now have a favorable market environment in which to develop and launch new medications and therapies as a result of the increased demand.

Restraints in the Global Atopic Dermatitis Drugs Market

The high price of medications for atopic dermatitis is a significant barrier to the global market for these treatments. Numerous cutting-edge treatments, such biologics, can be costly, which limits some patient populations' access to them. The high cost of these drugs may discourage people from using them and have a minor negative effect on the expansion of the market as a whole.

Market Trends of the Global Atopic Dermatitis Drugs Market

The growing emphasis on biologic therapy is a significant market trend in the global market for drugs treating atopic dermatitis. Treatment for moderate-to-severe atopic dermatitis has seen a major increase in interest in and acceptance of biologic medicines, such as monoclonal antibodies. With a focused approach to illness management, these medicines specifically target molecules and pathways involved in the immune response linked to the ailment. Because of their great efficacy and capacity for long-lasting remission, biologic treatments are becoming more and more popular as a viable therapy choice for patients who have not reacted well to conventional medications. This pattern illustrates how the field of atopic dermatitis is moving toward precision medicine and individualized treatment plans.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Atopic Dermatitis Drugs Market by Route of administration

Market Overview
Topical
injection and others

Global Atopic Dermatitis Drugs Market by Drug class

Market Overview
Biologics
PDE4 inhibitors
corticosteroids and others

Global Atopic Dermatitis Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GALDERMA LABORATORIES, L.P. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LEO Pharma Inc. (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meda AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pierre Fabre Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments